Cue Health
Pandemic-boom hardware companies rarely survive normalisation. Cue's at-home molecular test was clinically excellent but had no non-Covid demand curve.
Cue Health was a HealthTech / Molecular Diagnostics startup founded in 2010 in USA. It raised $480M+ (incl. 2021 IPO) before collapsing in 2024 — 14 years of runway burned. IdeaProof's AI Failure Score: 49/100, driven by post-covid demand collapse, fda authorization issues, cash-out failure. The shutdown affected employees, investors, and the broader HealthTech / Molecular Diagnostics ecosystem. This case study breaks down the timeline, root causes, competitors that won, and replicable lessons for founders validating similar ideas today.
Why did Cue Health fail?
Cue Health failed in 2024 after 14 years of operation, losing $480M+ (incl. 2021 IPO) in raised capital. The root cause was post-covid demand collapse, fda authorization issues, cash-out failure. Key lesson: Pandemic-boom hardware companies rarely survive normalisation. Cue's at-home molecular test was clinically excellent but had no non-Covid demand curve.
2010 → 2024
$480M+ (incl. 2021 IPO)
HealthTech / Molecular Diagnostics
USA
IdeaProof AI Failure Score
What Happened: The Timeline
2010
Founded in San Diego by Ayub Khattak and Clint Sever
2020-03
US government awards ~$481M in HHS/DoD contracts for Covid tests
2021-09-24
IPO on NASDAQ (HLTH) — valuation exceeds $3B
2022-2023
Post-Covid demand collapses; stock falls 95%+
2024-05-24
Lays off all remaining employees including executive team
2024-05-28
Files Chapter 7 in District of Delaware to wind down business
Root Causes
Cue Health built the first FDA-authorized at-home molecular Covid-19 test, reached a $3B+ IPO valuation on NASDAQ in Sep 2021, raised $480M+ total, and became one of the most-cited healthtech successes of the pandemic. Post-Covid demand collapsed 95%+ in 2022-2023, and in June 2024 the FDA revoked its Covid test authorization citing manufacturing issues. Cue laid off all remaining staff on 24 May 2024 and filed Chapter 7 bankruptcy on 28 May 2024 to wind down completely.
Causal Chain
This is our reading of the causal chain — separated from the verifiable facts above. Timeline dates, funding numbers and filings are facts (see methodology); root / proximate / terminal attribution is judgement based on public evidence.
Structural mismatch between burn rate and revenue growth: capital was consumed on scaling before unit economics turned positive, leaving no bridge when the next round failed to close.
- Single-purpose product (Covid) with no follow-on category
- FDA authorization revocation June 2024
- $481M government contracts couldn't offset consumer demand crash
- Failed to pivot to non-Covid molecular tests
2024-05-24: Lays off all remaining employees including executive team
2024-05-28: Files Chapter 7 in District of Delaware to wind down business
Base rates
A single failure is an anecdote. These base rates give you the denominator — how common this outcome is across all startups matching Cue Health's profile. Sources are third-party; we do not restate them as our own claims.
of failed startups cite "ran out of cash / could not raise" as the primary trigger — the most common terminal event across cycles.
CB Insights — Top 12 Reasons Startups Fail (2021)of digital-health startups fail to reach breakeven; reimbursement complexity + regulatory approvals extend runway needs beyond typical VC horizons.
Rock Health State of Digital Health (2023)of startups ultimately fail — including ~10% that fail in the first year and the rest across the following decade.
Startup Genome / CB Insights aggregate (2024)of new US employer businesses survive past their 10th year (Bureau of Labor Statistics BED series).
US Bureau of Labor Statistics — BED (2024)of Series A rounds ever graduate to Series B; the rest run out of runway or pivot without a follow-on.
CB Insights Venture Capital Funnel (2023)Key Lessons Learned
1. Pandemic-boom valuations are non-recurring
Cue's $3B IPO priced in Covid demand as a permanent baseline. When at-home testing volumes fell 95% in 2022, the entire capital structure was underwater within 18 months.
2. FDA authorization can be revoked as fast as it's granted
The June 2024 FDA action on manufacturing concerns removed Cue's core product from market days before Chapter 7 — regulated-medtech founders need contingency for post-market surveillance findings.
3. Government contracts are project revenue, not ARR
The ~$481M in HHS/DoD contracts made Cue look like a $500M+ ARR business; investors modelled it as recurring, but government hardware contracts are one-time by nature.
Frequently Asked Questions
Sources & Confidence
Every data point is tagged with its source type and our confidence in it. How we grade sources.
Could This Failure Have Been Prevented?
IdeaProof's AI validates market demand, competitive positioning, and business model viability in minutes — catching the exact issues that sank Cue Health.
Spotted a factual error?
Approved corrections are published in the public changelog with attribution.